Publication: EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
Open/View Files
Date
2013
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Landes Bioscience
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Concha-Benavente, Fernando, Raghvendra M Srivastava, Soldano Ferrone, and Robert L Ferris. 2013. “EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.” Oncoimmunology 2 (12): e27215. doi:10.4161/onci.27215. http://dx.doi.org/10.4161/onci.27215.
Research Data
Abstract
The epidermal growth factor receptor (EGFR) supports the escape of malignant cells from immunosurveillance by inhibiting the activation of signal transducer and activator of transcription 1 (STAT1) while promoting that of STAT3. We have recently demonstrated that protein tyrosine phosphatase, non-receptor type 11 (PTNP11, best known as SHP2), a phosphatase that operates downstream of EGFR, is responsible for the dephosphorylation of active STAT1 and for the inhibition of the antigen-processing machinery (APM), hence favoring tumor immunoescape. Thus, EGFR signaling may skew the tumor microenvironment to suppress cellular immune responses.
Description
Other Available Sources
Keywords
APM, EGFR, immunoescape, immunotherapy, pSTAT1, pSTAT3, SHP2
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service